BG Medicine and FDA to Conduct Joint Biomarker Discovery Study
Complete the form below to unlock access to ALL audio articles.
BG Medicine has announced the submission of a Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration's National Center for Toxicological Research (NCTR), to jointly conduct a liver toxicity study designed to overcome one of the primary obstacles to the efficient development of safe and effective drugs.
The study, Liver Toxicology Biomarker Study (LTBS), aims to discover biomarkers of human hepatotoxicity in the standard test used by pharmaceutical manufacturers in the initial stages of drug development.
The toxicity tests currently in use by drug companies have been unchanged for at least 40 years and often fail to identify human liver toxicity issues.
On March 16, 2004 the FDA released a report, “Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products,” describing the “urgent need to modernize the medical product development process - the Critical Path - to make product development more predictable and less costly.”
The proposed project addresses the liver toxicity issue highlighted in the Critical Path document as one of the obvious and priority areas for innovation.
The CRADA process is a standard procedure for studies the FDA undertakes in collaboration with private companies.
The liver toxicity study has been designed by BG Medicine and the FDA with input from a number of pharmaceutical companies.
The research project leverages NCTR's and BGM's systems biology platforms for functional genomics, proteomics, metabolomics and computational analysis.
The LTBS will be conducted at the FDA's NCTR laboratory in Jefferson, Arkansas and at BG Medicine in Waltham, Massachusetts.
The study is open to participation by all pharmaceutical manufacturers. Participating companies will receive a paid-up perpetual license to any biomarkers discovered and access to all project data.
